Bohen Sean 4

What Happened
Sean Bohen, President and CEO of Olema Pharmaceuticals, was granted two derivative equity awards on February 2, 2026 covering 850,000 and 275,000 shares (total 1,125,000) at $0.00 per share. These were awards/grants (not open-market purchases or sales), so no cash changed hands and there is no immediate realized value — these are potential future shares contingent on vesting and any exercise terms.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely; Form 4s are due within two business days).
• Award details: 850,000 and 275,000 share-related derivative awards, reported at $0.00 per share (derivative/award code "A").
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnote highlights:
  • F1 (time-based vesting): 25% of the shares subject to the option vest on Feb 2, 2027, then 1/48 of the total vests monthly thereafter, subject to continued service.
  • F2 (performance-based): The performance options vest only if specified 30-day average stock-price thresholds are met during one of two performance periods (Feb 2, 2026 to 12/31/2029 and to 12/31/2030); vesting is certified by the Compensation Committee.
  • F3 (severance protection): If the Reporting Person’s service is terminated without Cause, the performance-based options remain outstanding and eligible to vest for 12 months following termination.
• Transaction type: Award/grant of derivative securities (not a sale or purchase).

Context
These awards are compensation/retention instruments (time- and performance-based stock options or similar derivatives). They do not represent an immediate purchase of shares or a sale; any future ownership or value depends on meeting vesting conditions and, for options, any exercise. Awards are common for executives and should be viewed as part of long-term incentive arrangements rather than a straightforward bullish or bearish market signal.